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costs calculation in economic evaluations, measures used to calculate indirect cost, 
and difﬁculties while performing indirect costs estimation. Questionnaires were 
handed out to participants of the 3rd International Symposium Evidence-Based Health 
Care in Cracow, mailed to the Polish Pharmacoeconomic Society members and dis-
tributed directly to experts. RESULTS: Fifty four pharmacoeconomists, health econo-
mists and decision-makers returned completed questionnaires. Mean age of respondents 
33,3 o 7,6 years; mean experience in health economics 4,7 o 5,2 years; 43%(23/54) 
of responders had non-economic background, 41%(22/54) reported government as a 
work environment. All (excluding one) responders indicated that indirect costs should 
be calculated in pharmacoeconomic studies (strongly agree 58%, agree 40%). Experts 
pointed out that indirect cost were calculated in only 24% of reports and represented 
on average 22% of total costs. Twenty three (i.e. 43%) responders indicated human 
capital approach as the best method to estimate cost from societal perspective; friction 
cost method came second best 11%(6/53); 42%(22/53) respondents had no opinion. 
The doers of economics evaluations pointed to GDP per capita (11/18), average salary 
(11/18), and costs of sick pay or injury beneﬁt (11/18) as measures which should be 
used to value production losses. CONCLUSIONS: Indirect costs are considered impor-
tant but seldom executed component of economic evaluations of health care interven-
tions in Poland. The lack of consensus and widely accepted methods for indirect cost 
evaluation support further research.
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OBJECTIVES: Through the increase of economic evaluation studies in Korea, the 
question of transferability from different settings is becoming more and more impor-
tant. However, there are factors that may limit the transferability of study results 
such as variations in the epidemiology, relative pricing and the availability of health 
care resources. Already published by Welte, Boulenger and Urdahl, transferability 
tools are useful and easy to check the transferability among countries. This study 
assessed the transferability with these tools from other settings to Korea settings. 
METHODS: With three selected articles conducted in Belgium, Sweden and USA, 
we evaluated the transferability to Korean settings using 3 methodologies (Welte, 
Boulenger and Urdahl) and then identiﬁed those factors that can be appropriate 
to adapt in Korea settings. RESULTS: In case of Welte, Belgium and US study 
showed low correspondence for disease incidence like 0.4% vs. 0.01% in THR. And 
Sweden study showed different case-mix that the average age of TKR patients were 
higher than THR but Korea case was opposite. According to Boulenger method, the 
scores for Belgim, Sweden and US studies were 51.5, 75 and 75.6 separately. 
Low scores came from the discount and cost mainly due to insufﬁcient description. 
With Urdahl method, three studies well expressed for decision maker, but Belgium 
and Sweden studies did not describe the clinical research enough. The United 
States study explained in detail for the transition probabilities and modeling but the 
unit price and resource use were not related to Korea setting directly due to different 
pricing system. CONCLUSIONS: Through this evaluation, disease incidence, unit 
price and resource use showed low transferability in order to transfer to Korea. We 
could ﬁnd out that data and methods should be presented in a transparent way to 
improve transferability.
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OBJECTIVES: To evaluate an online, freeware, incremental cost-effectiveness calcula-
tor that generates and plots results from a decision tree that utilizes Monte Carlo 
simulations for the variables related to the success probabilities, costs and utilities. 
METHODS: An online cost-effectiveness calculator and plotter were developed that 
incorporates a decision tree structure with Monte Carlo simulations to compare two 
interventions. This decision analysis calculator is available at www.healthstrategy.
com. This online tool uses JavaScript algorithms and was based on an MS Excel model 
description published by Hughes D. His spreadsheet can be downloaded from www.
liv.ac.uk/prg/model.xls. For this evaluation, the spreadsheet structure was modiﬁed 
slightly to match the more basic online tree. Log-normal and beta distributions are 
generated from variable inputs that can be modiﬁed in the web-based software that 
cover costs, utilities and probability of both success and failure for two treatment 
alternatives. RESULTS: The online calculator functions on most computer operating 
systems with JavaScript enabled browsers. The web-based tool creates a scatter plot 
of incremental costs versus incremental utilities in cost-effectiveness quadrants, and 
also graphs a cost-effectiveness acceptability curve. Although the min-max range of 
cost results were similar between the two tools, the range of utility results was greater 
with the web computations. The MS Excel spreadsheet model (1000 simulations) 
versus the online calculator (500 simulations) compared as follows: average incremen-
tal costs ($1919 vs. $1885), average incremental utilities:(0.058 vs. 0.054) and average 
incremental cost effectiveness ratio:($33,086 vs. $34,907). CONCLUSIONS: With 
this online decision tree and Monte Carlo simulator, the user can input their own 
distribution parameters, then generate and graph incremental costs, incremental utili-
ties and cost effectiveness acceptability curves. This web-based calculator has potential 
beneﬁt as a basic educational tool for students and health professionals interested in 
exploring these analytical approaches.
PMC20
IMPLEMENTING A BENCHMARKING MODEL FOR EXPENDITURES OF 
PRESCRIPTION DRUGS IN AUSTRIA
Heiderer B, Ortner T, Pfeffer N
Main Association of Austrian Social Security Institutions, Vienna, Vienna, Austria
OBJECTIVES: Since 2005 Austrian regional sickness funds have been facing an 
increase in drug prescription costs of 7–8 % per year. In order to analyze these 
costs we developed a benchmarking system comparing drug prescription costs 
for 2007 of the regional sickness funds including two ratios split into a price and a 
volume component. Calculating the ratios at the high aggregate of the second 
ATC level revealed problems: The total savings potential seemed unrealistically high 
and could not be traced back to a speciﬁc ﬁeld of action. Therefore, the need for a 
re-design of the benchmarking system was more than necessary. METHODS: Since 
the cost-function is interpreted as a function of the distribution of prescriptions, price 
effects can be shown by adjusting the distribution. This is equivalent to shifting pre-
scriptions from speciﬁc drugs to others within a cluster. To legitimize this new method, 
the volume component of each sickness fund is normalized to the average level of 
prescriptions per beneﬁciary (ATC level 2), considering the fund’s distribution of pre-
scriptions in lower ATC levels. The process of clustering starts with substitutable drugs 
according to the national eco-list. After that these clusters are combined to groups at 
ﬁrst ATC level 5 and then ATC level 4. Within these groups the distributions of the 
funds are adjusted to the benchmark’s distribution. RESULTS: In each step of the 
clustering process we used various approaches, like the use of the eco-list or substitu-
tion of drugs by similar agents, to affect the price component. Moreover, the new 
method evaluates the prescription behaviour of contract physicians for each fund. 
CONCLUSIONS: The original method shows that a savings potential cannot be cal-
culated on an aggregate level. The new method provides a more detailed, step-by-step 
analysis and allows to identify—combined with medical quality assurance—possible 
ﬁelds of action.
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OBJECTIVES: Absenteeism costs estimated based on amount of mean sick pay (data 
provided by Social Insurance Institution—ZUS) were calculated for approximately 
a2.3 billion in 2007. The aim of this study was to evaluate the difference between 
absenteeism costs estimated either on mean sick pay or on gross value added in Poland 
in 2007. METHODS: Sickness absence data were derived by ZUS. Alternatively to 
ZUS data, absenteeism cost was estimated based on gross value added and structure 
of employed persons by sectors in sections of national economy derived by Central 
Statistical Ofﬁce (GUS). Based on ZUS and GUS data we calculated value of missed 
day per employed in speciﬁc sector of the economy. The analysis was based on an 
assumption that number of missed days includes only working days (252 days per 
year). Human capital approach was used to estimate the absenteeism costs. Values 
are presented in Euro (exchange rate: 1 Euro  4.50 PLN). RESULTS: Absenteeism 
costs were estimated to amount of a12 billion. Cost of missed days of work due to 
illness per person employed in mining and quarrying (a2062) was more than 5 times 
higher than cost per person employed in education (a380). Mean cost of absenteeism 
was estimated to amount of a1012 per employee. Mean cost of absenteeism estimated 
based on gross value added was more than 6 times higher than those estimated based 
on amount of funds spent on sick pay (a154 per employee). CONCLUSIONS: Given 
that ZUS data on amount of mean sick pay seem to provide reliable absenteeism costs 
in Poland, it would seemed that either data based on wages are underestimated or 
some compensative mechanisms exist in economy that limit indirect cost of sickness 
absence.
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Alcoholism is a chronic disease and the evaluation of its burden usually focuses on 
long-term co-morbidity and mortality. Clinical Trials evaluating new interventions for 
alcohol-dependent patients rarely last more than 12 to 24 months. OBJECTIVES: 
Develop a questionnaire capable of capturing principal resource use yet sensitive 
enough to show short-term economic beneﬁt of drugs developed to reduce consump-
tion in alcohol-dependent patients. METHODS: Comprehensive Medline literature 
search using keywords: Alcohol-related-disorders, economics, cost of illness. Further, 
experts panel discussions provided additional data. RESULTS: Two key cost drivers, 
hospitalisation and sick leaves were identiﬁed by the literature review. Expert ﬁndings 
related to costs of social consequences were incorporated. These three important 
resources were included in the questionnaire in addition to standard medical resource 
use consumption input. Finally, the following items were included: consultation visits, 
hospitalisations, sick leaves and working situation, living situation, social environ-
ment, accidents, arrests and domestic violence. The recall period is 3 months. DISCUS-
SION: A great deal of information is collected in this questionnaire in order to capture 
all relevant resources. Tests to validate the questionnaire in a real-life setting will be 
conducted (face validity, concurrent validity, and test-retest) in a cohort of dependent 
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patients initiated at Lausanne University hospital ( Switzerland). Items not sensitive 
enough to capture short-term costs and consequences will be removed. Translation 
into other major languages and adaptation to different settings after cultural validation 
is planned. CONCLUSIONS: Publication of this tool should facilitate additional 
knowledge about resource utilisation at the patient level and enable evaluation 
of short-term economic impact of pharmacological and non-pharmacological 
interventions.
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This work addresses the problem that common measures of uncertainty of cost-
 effectiveness, ie, cost-effectiveness acceptability curves and the expected value of 
perfect information (EVPI), may be biased by overestimating clinical effectiveness and 
underestimating uncertainty. Reasons are small randomized controlled trials (RCTs) 
as the underlying source of effectiveness data and the overoptimistic, albeit implicit, 
assumption that the prior probability of the null hypothesis being false is 50%. If 
clinical evidence is based on small RCTs with sensitivity and speciﬁcity of 65% and 
70%, respectively (LeLorier 1997), the maximum probability of cost-effectiveness 
decreases to 68%, irrespective of the willingness to pay. If, in addition, a 10% prior 
probability of effectiveness is assumed (Sterne 2001), the maximum probability of 
cost-effectiveness drops to 19%. Similarly, the EVPI increases 8-fold if low sensitivity 
and speciﬁcity of small RCTs as well as a 10% prior probability of effectiveness are 
considered. Therefore, traditional CEACs and EVPI analyses based on small RCTs 
and an implicit 50% prior probability of the null hypothesis being false should be 
reassessed.
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OBJECTIVES: to optimize the selection of surgical patients for treatment in a given 
time period, subject to the extant resource allocation scenario and constraints on the 
utilization of those resources. METHODS: Sampson is a software tool that uses a 
quantitative, goal oriented approach to optimize the utilization of health care 
resources. The Sampson optimization module accepts a surgical waiting list as an input 
value, and selects a set of patients for treatment in a given time period that will keep 
waiting times below target Maximum Acceptable Waiting (MAW) times, subject to 
alternative allocation of health care resources. These resources include operating room 
(OR) time, Special Care Unit (SCU) time, OR nursing time, anesthetist time, surgical 
cost and aftercare cost. Additional determinants of system performance which are 
factored into the Sampson patient selection process are changes in staff availability, 
patient care policies and MAW values by surgical procedure. Evaluation of Sampson’s 
predictions of system performance under different resource allocation scenarios and 
policy sets is intended to provide decision support to system managers. Furthermore, 
the use of the Sampson patient selection set is intended to optimize efﬁciency within 
a potentially complex organizational structure, including health regions, hospitals, 
surgical divisions and surgeons. The surgical waiting list used as an input by the 
Sampson optimization module may be extracted from a surgical center’s operational 
data systems, or may be produced by a patient arrivals simulation process. The arrivals 
simulation is based on the historical arrival pattern and expected future changes to 
that pattern. RESULTS: An example scenario is presented which compares the pre-
dicted outcomes of three different resource allocation options for a two hospital surgi-
cal system. CONCLUSIONS: The results have signiﬁcant implications for policy 
makers and health service researchers interested in optimization of resource allocation 
decisions and minimizing the waiting time for surgical treatment.
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OBJECTIVES: Migraine is a common and disabling condition. Real-world health care 
resource utilization and patient reported outcomes data are important for document-
ing the burden of illness and are necessary inputs for economic models. An efﬁcient 
and adaptable methodology for the conduct of international health economic and PRO 
data gathering is described. METHODS: An IRB approved, web-based, cross-sectional 
survey of headache sufferers was conducted in 9 countries (US, Canada, Australia, 
UK, Germany, France, Spain, Italy, Taiwan). Registered panelists received email invita-
tions in their country’s language and provided consent from a web link option; non-
migraineurs were excluded on the basis of reported symptoms, and eligible subjects 
were classiﬁed as either chronic (q15 headache days per month), episodic (1–14), or 
potential migraineurs (migraine-like symptoms). Survey enrollment was rolled out in 
waves and completed when targeted sample of chronic migraineurs was obtained. 
Survey outcomes included sociodemographic, headache symptoms, resource utiliza-
tion, disability and productivity from HIT-6, MIDAS, MSQ v2.1. Validation rules 
were pre-programmed to enhance data quality. RESULTS: Of 63,001 survey invitees, 
20,987 responded. A total of 9118 completers (14.5%) comprised the ﬁnal cohort (n 
 516 ( Australia)—1597 (US)); 83.6% female; mean age 41 (o12) years; 499 (5.5 %) 
chronic migraineurs. Mean study period across countries was 12.6 days; results were 
available within 3–5 days after study completion. The core survey required minimal 
adaptation for international use beyond translation, permitting both country-speciﬁc 
and pooled analyses. Main challenges included adapting questionnaires to a web-based 
format and predicting eligibility rates for countries without pre-screened headache 
survey candidates. Despite inherent limitations of on-line studies, particularly gener-
alizability, the observed proportion of chronic to episodic migraineurs within a head-
ache population was consistent with other published reports using mailed 
questionnaires. CONCLUSIONS: International, web-based, patient-reported surveys 
are a method of collecting clinical, resource utilization and PRO data, while minimiz-
ing time and cost.
CONCEPTUAL PAPERS & RESEARCH ON METHODS – Databases & 
Management Methods
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OBJECTIVES: Link person-level inpatient drug and service utilization data with pre-
admission and post-discharge histories, using nationally-representative hospital dis-
charge and managed care claims databases. METHODS: Linkages were developed 
from two de-identiﬁed health care databases: 1) discharge summaries and detailed 
billing data for the complete census of discharges from 171 US hospitals; 2) claims 
for inpatient services paid to these hospitals by private and public health plans that 
contribute to the MarketScan Research Databases. Hospital discharge records were 
sorted by hospital name, patient year of birth, sex, principal diagnosis, date of admis-
sion, and date of discharge, and cases were identiﬁed that were uniquely identiﬁed by 
these variables. Paid claims were then searched for matching records with the same 
combination of the six variables. These were considered to be the same patient, given 
that each combination of matching variables was unique within the hospital census. 
To understand how this convenience sample relates to the universe of discharges from 
US hospitals, linked discharges were compared to the 2006 National Inpatient Sample 
(NIS). RESULTS: For 2006 there were 77,277 linked discharges. Compared with NIS, 
more were in Medicaid (52% v. 20%) and fewer in Medicare (20% v. 37%) or com-
mercial (29% v. 34%) health plans, reﬂecting the payer mix of the claims database. 
They were younger (44 v. 48 years) and more female (67% v. 58%) than NIS. Average 
length of stay was 4.6 days in both samples. Of the top 10 most frequent DRGs in 
NIS, accounting for 31% of US discharges, 8 were also in the top 10 of the linked 
sample. CONCLUSIONS: Patient-level hospital discharge data can be enhanced by 
linking it to longitudinal histories from health plan administrative data. Judicious use 
of this resource for outcomes research requires understanding potential selection 
biases.
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OBJECTIVES: Health care decision makers assessing the cost-effectiveness of health 
care technologies seek evidence from economic evaluations. As well as searching eco-
nomic evaluation databases such as NHS EED and HEED, researchers often search 
MEDLINE and EMBASE, using sets of search terms or search ﬁlters whose current 
performance is unclear. We tested the performance of search ﬁlters in identifying eco-
nomic evaluations from MEDLINE and EMBASE. METHODS: A reference standard 
set of economic evaluations was identiﬁed from NHS EED published in 2000, 2003 
and 2006. The MEDLINE and EMBASE records corresponding to those evaluations 
were retrieved. Search ﬁlters were identiﬁed from the InterTASC Information Special-
ists’ SubGroup website and from Canadian Agency for Drugs and Technologies in 
Health (CADTH) staff and reviewers. The sensitivity and precision of search ﬁlters in 
retrieving the reference standard records from MEDLINE and EMBASE were tested. 
RESULTS: A total of 2070 full economic evaluations were identiﬁed from NHS EED. 
Of these 1955 had matching records in Ovid MEDLINE and 1873 had matching 
records Ovid EMBASE. 13 MEDLINE and 8 EMBASE ﬁlters were identiﬁed. 3 ﬁlters 
achieved greater than 0.99 sensitivity in MEDLINE and four in EMBASE. Filters 
demonstrated low precision. CONCLUSIONS: This research provides new perfor-
mance data on search ﬁlters to identify economic evaluations in MEDLINE and 
EMBASE and indicates which ﬁlters may assist dependent on searchers’ priorities. It 
remains difﬁcult to identify economic evaluations reliably whilst achieving reasonable 
levels of precision.
